Bethany Girard, Ph.D.

Moderna, Inc.

Poster(s):

• (367) Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (2363) Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2655) Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET